neoplasm
• tumor bearing mice treated with the geldanamycin analogue, 17-AAG, which inhibits Hsp90, show a transient degeneration of tumors
(J:128700)
• mice treated with doxycycline develop lung adenocarcinomas
(J:213447)
• mice treated with doxycycline, followed by treatment with a tyrosine kinase inhibitor erlotinib, initially show tumor regression but eventually develop tumors resistant to long-term erlotinib treatment
(J:213447)
• treatment of doxycycline treated mice that have erlotinib-resistant tumors with a MEK inhibitor, trametinib, results in tumor regression
(J:213447)
• treatment of doxycline treated mice with trametinib alone does not have an effect on tumor growth
(J:213447)
|
respiratory system
• tumor bearing mice treated with the geldanamycin analogue, 17-AAG, which inhibits Hsp90, show a transient degeneration of tumors
(J:128700)
• mice treated with doxycycline develop lung adenocarcinomas
(J:213447)
• mice treated with doxycycline, followed by treatment with a tyrosine kinase inhibitor erlotinib, initially show tumor regression but eventually develop tumors resistant to long-term erlotinib treatment
(J:213447)
• treatment of doxycycline treated mice that have erlotinib-resistant tumors with a MEK inhibitor, trametinib, results in tumor regression
(J:213447)
• treatment of doxycline treated mice with trametinib alone does not have an effect on tumor growth
(J:213447)
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
lung cancer | DOID:1324 |
OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210 |
J:128700 , J:213447 |